Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

MOTS-c 10 mg

$91Per Unit

Research-grade peptide with certificate of analysis, HPLC verification, and cold-chain compliant packaging from our Chicago distribution center.

Lot M2025-08A · COA on request
Lyophilized peptide, sterile stoppered vial
2–8°C

5 × $91.00 = $455.00 $295.75 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

MOTS-c 10 mg

$295.75 for 5 · 35% off

Research use only
MOTS-c 10 mg research packaging
Lyophilized peptide, sterile stoppered vial
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot M2025-08A) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

MOTS-c

Regulatory status
Not approved. FDA lists MOTS-c among substances that may present significant safety risks in compounding. A phase 2 trial in prediabetes is registered and recruiting.
Strongest evidence
Animal studies; human trials only beginning
Overview

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described in 2015 as a regulator of metabolism and insulin sensitivity.

What researchers study it for
  • Insulin sensitivity and metabolic health
  • Diet-induced obesity (mouse models)
  • Exercise and muscle metabolism research
Mechanism

In the original study its primary target was skeletal muscle, where it inhibited the folate cycle and activated AMPK, an energy-sensing enzyme.

Evidence (3)
  1. Animal study

    Discovery study (Cell Metabolism, 2015)

    In mice, MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity.[1]

  2. Trial registry

    Human trials

    A phase 2 trial of MOTS-c for insulin sensitivity in prediabetes is recruiting (NCT07505745). An analog, CB4211, completed a phase 1a/1b study (NCT03998514).[2][3]

  3. Regulatory

    FDA compounding risk list

    FDA states it lacks important information about MOTS-c safety in humans.[4]

Limitations of the evidence
  • No published human efficacy results for MOTS-c itself.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (4)
  1. 1.The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceLee C et al. Cell Metab. 2015 Animal study
  2. 2.MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityClinicalTrials.gov NCT07505745 Trial registry
  3. 3.A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver DiseaseClinicalTrials.gov NCT03998514 Trial registry
  4. 4.Certain bulk drug substances for use in compounding that may present significant safety risks (lists MOTS-c)U.S. FDA, page current as of Apr 22, 2026 Regulatory
Every published studyPubMed search: MOTS-c(opens in a new tab)Every registered trialClinicalTrials.gov search: MOTS-c(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.